Bacteria in dental biofilm cause 95% of the oral diseases. Lumoral® eliminates pathogenic bacteria and reduces plaque buildup to the surface of the teeth and gum line. Lumoral has been clinically proven in randomised trials to treat peridontal disease.
If gingivitis is left untreated, the gum pockets will deepen, creating favourable conditions to pathogenic, anaerobic periodontal bacteria to thrive.
The resulting dysbiosis in the gingival pocket will trigger an inflammatory response. Immune cells release chemicals that can damage the connective tissue fibres attaching the tooth to the bone supporting the teeth.
Lumoral® is an advanced and patented medical device that treats and prevents oral diseases.
Europe's largest study on periodontitis confirms, that Lumoral significantly improves golden standard treatment outcomes for gum disease.
54% of the periodontal patients using Lumoral at home reached gum health (BOP<10%) in a 3 months study period. Regular use of Lumoral at home reduces gum inflammation and improves oral hygiene. It reduces deep pockets, multiplying the effectiveness of the professional non-surgical periodontal treatment. The results are consistent with the experience of thousands of Lumoral users and dentists.
Pakarinen S et al. Home-Applied Dual-Light Photodynamic Therapy in the Treatment of Stable Chronic Periodontitis (HOPE-CP)—Three-Month Interim Results. Dentistry J. 2022; 10(11):206.https://doi.org/10.3390/dj10110206
Control Every: 12 months
✓ Mild gingivitis
✓ Prevention of bacterial dental diseases
✓ Moderate risk for caries
✓ Moderate tartar formation
✓ Bad breath
Periodontitis treatment: patients with stable treatment results and without additional risk factors.
Control Every: 3 months
✓ High caries risk
✓ Moderate gingivitis
✓ Severe tartar formation
✓ Periodontitis stage 1-2
✓ aMMP-8 above 20 ng / ml
Periodontitis treatment: patients with additional risk factors such as diabetes mellitus, cardio-vascular disease or smoking, long-term therapy is recommended.
Control Every: 1 months
✓ Severe gingivitis
✓ Periodontitis stage 3-4
✓ aMMP-8 significantly elevated
With intensive therapy, the light activation can be increased to up to 30 minutes for every Lumorinse dose. (Longer treatment time increases the antibacterial effect).
EUROPE AND OTHER MARKET AREAS
Tero Pasanen – CCO
tero.pasanen(at)koitehealth.com
+358 40 045 9080
SOUTHERN FINLAND
Riikka Nisula – Lumoral Area Manager
riikka.nisula(at)koitehealth.com
+358 40 753 3214
CENTRAL AND NORTHERN FINLAND
Emilia Kataja – Lumoral Area Manager
emilia.kataja(at)koitehealth.com
+358 40 518 5488
STOCKHOLM AREA + SWEDEN
Helen Huttunen – Country Manager
helen.huttunen(at)koitehealth.com
+46 73 560 0092